Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: -2.4%
1M: -6.8%
3M: -14.9%
YTD: +17.0%
1Y: -20.6%
3Y: +29.6%
5Y: -33.1%
$31.80
-0.68 (-2.09%)
Weekly Expected Move ±4.6%
$29
$30
$32
$33
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-04-02
Earliest Filing
2024-05-28
Latest Filing
supplier: 2
investor: 1
acquirer: 1
partner: 1
Counterparties (Filed by AGIO)
5 relationshipsCompanies named in AGIO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Royalty Pharma Investments 2019 ICAV | RPRX | investor | Purchased 15% of U.S. net sales earn-out for vorasidenib from Agios Pharmaceuticals | 2024-05-28 | View |
| Servier Pharmaceuticals, LLC | — | supplier | Original counterparty obligated to pay earn-out on vorasidenib sales | 2024-05-28 | View |
| Servier S.A.S. | — | supplier | Guarantor of Servier Pharmaceuticals, LLC obligations under the Counterparty Agreement | 2024-05-28 | View |
| Servier Pharmaceuticals, LLC | — | acquirer | Purchaser of Oncology Business assets | 2021-04-02 | View |
| Servier S.A.S. | — | partner | Guarantor for Purchaser's obligations | 2021-04-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-06-18 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-04 | Regulation FD Disclosure | View | |
| 2025-07-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-08 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-18 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-02-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-01-06 | Regulation FD Disclosure | View | |
| 2024-10-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-06-20 | Submission of Matters to a Vote of Security Holders | View | |
| 2024-05-28 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2024-05-02 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-02-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR